All In Biotech

Drug Trial Radar · NCT04197687

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Phase II Trial to Evaluate Immune-Related Biomarkers for Pathological Response in Stage II-III HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Subsequent Randomization to Multi-Epitope HER2 Vaccine vs. Placebo in Patients With Residual Disease Post-Neoadjuvant Chemotherapy

Last checked: Nov 19, 2026Latest source record: Dec 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

480

Planned (sponsor's estimate)

Start

Feb 20, 2020

Primary completion

Jan 15, 2025

Study completion Jan 15, 2025

Sponsor

Lead sponsor
Academic and Community Cancer Research UnitedAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Dec 13, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well TPIV100 and sargramostim work in treating patients with HER2 positive, stage II-III breast cancer that has residual disease after chemotherapy prior to surgery. It also studies why some HER2 positive breast cancer patients respond better to chemotherapy in combination with trastuzumab and pertuzumab. TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim increases the number of white blood cells in the body following chemotherapy for certain types of cancer and is used to alert the immune system. It is not yet known if TPIV100 and sargramostim will work better in treating patients with HER2 positive, stage II-III breast cancer.

Conditions

  • Breast Adenocarcinoma
  • Stage II Breast Cancer AJCC v6 and v7
  • Stage IIA Breast Cancer AJCC v6 and v7
  • Stage IIB Breast Cancer AJCC v6 and v7
  • Stage III Breast Cancer AJCC v7
  • Stage IIIA Breast Cancer AJCC v7
  • Stage IIIB Breast Cancer AJCC v7
  • Stage IIIC Breast Cancer AJCC v7

Interventions

  • Multi-epitope HER2 Peptide Vaccine TPIV100Biological

    Given ID

  • PertuzumabBiological

    permitted at physician's discretion

  • Placebo AdministrationOther

    Given ID

  • SargramostimBiological

    Given ID

  • TrastuzumabBiological

    therapy are at the discretion of the treating physicians

  • Trastuzumab EmtansineBiological

    at the discretion of the treating physicians.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive disease-free survival (iDFS) between the 2 armsTime frame: From time of randomization to recurrence, invasive breast cancer or death, assessed up to 5 years

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona

    Scottsdale, Arizona · Recruiting

  • Banner University Medical Center - Tucson

    Tucson, Arizona · Recruiting

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona · Recruiting

  • Yuma Regional Medical Center

    Yuma, Arizona · Withdrawn

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Withdrawn

  • UC San Diego Moores Cancer Center

    La Jolla, California · Not yet recruiting

  • Middlesex Hospital

    Middletown, Connecticut · Withdrawn

  • University of Florida Health Science Center - Gainesville

    Gainesville, Florida · Recruiting

  • Mayo Clinic in Florida

    Jacksonville, Florida · Recruiting

  • Cleveland Clinic Florida

    West Palm Beach, Florida · Withdrawn

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia · Not yet recruiting

  • Illinois CancerCare-Peoria

    Peoria, Illinois · Withdrawn

  • Carle Cancer Center NCI Community Oncology Research Program

    Urbana, Illinois · Withdrawn

  • Siouxland Regional Cancer Center

    Sioux City, Iowa · Withdrawn

  • University Medical Center New Orleans

    New Orleans, Louisiana · Recruiting

  • University of Maryland/Greenebaum Cancer Center

    Baltimore, Maryland · Not yet recruiting

  • Essentia Health NCI Community Oncology Research Program

    Duluth, Minnesota · Withdrawn

  • Mayo Clinic in Rochester

    Rochester, Minnesota · Recruiting

  • Coborn Cancer Center at Saint Cloud Hospital

    Saint Cloud, Minnesota · Withdrawn

  • Washington University School of Medicine

    St Louis, Missouri · Withdrawn

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

    Lebanon, New Hampshire · Recruiting

  • FirstHealth of the Carolinas-Moore Regional Hospital

    Pinehurst, North Carolina · Recruiting

  • Guthrie Medical Group PC-Robert Packer Hospital

    Sayre, Pennsylvania · Withdrawn

  • Lexington Medical Center

    West Columbia, South Carolina · Withdrawn

  • Vanderbilt University/Ingram Cancer Center

    Nashville, Tennessee · Not yet recruiting

  • Inova Fairfax Hospital

    Falls Church, Virginia · Withdrawn

  • Marshfield Medical Center-EC Cancer Center

    Eau Claire, Wisconsin · Not yet recruiting

  • Saint Vincent Hospital Cancer Center Green Bay

    Green Bay, Wisconsin · Withdrawn

  • Dean Hematology and Oncology Clinic

    Madison, Wisconsin · Withdrawn

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.